If yu de fɛt kansa, ɔr if yu gɛt pɔrsin wae yu lɛk wae gɛt am, yu go mɔs no bɔt wɔd dɛm lɛk "kimotɛrapi" ɛn "rɛdyushɔn tɛrapi." Yu go dɔn yɛri bɔt di sayd ɛfɛkt dɛm wae kin kam wit dɛn tritmɛnt ya. Bɔt tide wi go tɔk bɔt wan rili nyu klas fɔ drɔgs we de tɔch ɔl di kansa sɛl dɛn ɛn ridyus di damej to wɛlbɔdi sɛl dɛn bad bad wan. Dɛn kɔl dɛn tin ya PARP Inhibitors .
Fɔ tɔk am simpul wan, wetin na dis PARP Inhibitor?
Fɔ ɔndastand dis, wi nid fɔ ɔndastand fɔs wan smɔl bɔt rili impɔtant tin we kin apin insay di sɛl dɛn na wi bɔdi. Insay ɔl di sɛl dɛn na wi bɔdi, sɔntin de we dɛn kɔl DNA. Tink bɔt am lɛk big bluprint we dɔn rayt aw ɔltin na wi bɔdi fɔ wok. Sɔntɛnde, di pej dɛn na dis DNA blueprint kin pwɛl smɔl.
dis na di say we wan protin we dεn kכ l PARP de kam insay. "PARP" na abbrevieshɔn fɔ Poly (ADP-ribose) polimeraz . PARP tan lεk "ripa mεkanik" insay wi sεl dεm. we di DNA dכn pwεl, di PARP protin de go insay εn ripεr am. Dis impɔtant fɔ mek di sɛl dɛn we gɛt wɛlbɔdi go kɔntinyu fɔ liv.
Bɔt di prɔblɛm na dat, di kansa sɛl dɛn kin yuz dis PARP mɛkanism bak fɔ dɛn bɛnifit. we di DNA fכ di kεnsar sεl dεm dεn dכn pwεl, dεn de yuz dis PARP bak fכ ripεr am. Dis kin mek di kansa sɛl dɛn nɔ de day, bɔt dɛn kin kɔntinyu fɔ gro ɛn skata ɔlsay na di bɔdi.
As sɔlv fɔ dis, dɔktɔ dɛn kin yuz wan mɛrɛsin we dɛn kɔl PARP Inhibitor. "Inhibitor" min "blɔk." wetin dis dכg de du na fכ "bכk" di PARP mεkanism we de εp di kεnsar sεl dεm. If PARP nɔ ɛp am, di kansa sɛl kin wik smɔl smɔl, i nɔ kin ebul fɔ mek di DNA we dɔn pwɛl, ɛn leta i kin day.
dis tan lεk fכ כf di kεnsar sεl in "sכvayv sistεm." Na dat mek dɛn kin kɔl dis tritmɛnt we dɛn kin du bak targeted therapy . Dat min se dɛn mɛrɛsin ya de tɔch wan wikɛd tin we de na di kansa sɛl dɛn dairekt wan.
di men kayn PARP inhibito dεm we dεn de yuz na di wכl
Bɔku PARP inhibito dɛn de we dɛn dɔn gri fɔ naw fɔ trit kansa. If yu dɔktɔ gi yu wan pan dɛn tin ya, i kin de pan dis list.
| Jɛnɛrik Nem fɔ di Mɛdisin | Brand Nem fɔ di kɔmni |
|---|---|
| Olaparib we dɛn kɔl Olaparib | Lynparza® we dɛn kɔl Lynparza |
| Niraparib we dɛn kɔl Niraparib | Zejula® we gɛt fɔ du wit am |
| Rukaparib we gɛt di sik | Rubraca® we gɛt fɔ du wit am |
| Talazoparib we gɛt di sik | Talzenna® we dɛn kɔl |
Us kayn kansa dɛn kin yuz dis mɛrɛsin fɔ?
PARP inhibito dεm dεn kin yus fכ kεnsar dεm we dכn go bifo כ we dεn spre to כda pat dεm na di bכdi (mεtastatik). Bɔku kayn kansa de we dɛn kin rili wok fɔ.
- Brɔst kansa
- Kansa na ovarian
- Falopian tiub kansa
- Prɔstat kansa
- Praymari peritoneal kansa
- Kansa na di pankrias
di spεshal rilayshכn wit BRCA jin mכtεshכn dεm
Na dis na sɔntin we yu rili nid fɔ no bɔt di BRCA jin . BRCA na ɔda impɔtant jin we de ɛp fɔ mek di DNA we de na wi sɛl dɛn fayn ɛn mek wi nɔ gɛt kansa. Bɔt sɔm pipul dɛn kin gɛt wan chenj na dis BRCA jin. dis min se wan pan dεn men DNA ripa sistεm dεm nכ de wok fayn. Bikɔs ɔf dis, dɛn kin gɛt bɔku kansa.
Tink bɔt motoka lɛk se i gɛt tu brek sistem. BRCA na wan, ɛn PARP na di ɔda wan. insay wan kεnsar sεl we gεt BRCA jin mכtεshכn, wan brek sistεm (BRCA) dכn כlrεdi brok. So dat kansa sɛl de dipen ɔlmost pan di ɔda brek sistɛm (PARP) fɔ mek i kɔntinyu fɔ liv.
Naw we wi gi PARP Inhibitor drɔgs, wi de ɔf da sɛkɔn brek sistɛm de bak. Dɔn di kansa sɛl nɔ gɛt we fɔ mek in DNA fayn, ɛn i jɔs de day. Dis na di rizin we mek PARP Inhibitors so effektiv fכ kansa wit BRCA jin mכtεshכn.
Aw a kin gɛt di tritmɛnt ɛn aw lɔng i kin tek?
Wan pan di fayn tin dɛm fɔ dis tritmɛnt na dat ɔltin kin kam insay pil fɔm (kapsul ɔ tablɛt). So yu fɔ tek dis mɛrɛsin wan ɔ tu tɛm nɔmɔ insay di de. Sɔntɛnde, dis mɛrɛsin nɔmɔ kin du fɔ am. Ɔda tɛm dɛn, yu kin nid fɔ tek am wit ɔda tritmɛnt dɛn fɔ kansa.
Fɔ ɛgzampul, afta yu dɔn du tritmɛnt we de pwɛl di DNA fɔ di kansa sɛl dɛn, lɛk kemotɛrapi ɔ redyushɔn tɛrapi, yu kin gi wan PARP inhibitor. Dɔn, bikɔs PARP nɔ de ɛp dɛn kansa sɛl dɛn de we dɔn pwɛl fɔ mek dɛnsɛf fayn, dat go mek dɛn sɛl dɛn de day.
Di tɛm we dɛn de trit am
Dis kin difrɛn frɔm wan pɔsin to ɔda pɔsin.
- Dɛn kin gi sɔm pipul dɛn dis mɛrɛsin fɔ wan patikyula tɛm, lɛk tu ɔ tri ia, afta dɛn dɔn dɔn di tritmɛnt we dɛn de gi di kemotɛrapi.
- Sɔm pipul dɛn kin kɔntinyu fɔ tek dis mɛrɛsin as lɔng as i de wok fɔ dɛn bɔdi.
- Sɔntɛnde, if di sayd ɛfɛkt dɛn pas di bɛnifit dɛn we di mɛrɛsin gɛt, yu kin tɔk to yu dɔktɔ ɛn stɔp di tritmɛnt.
So, i rili impɔtant fɔ tɔk to yu dɔktɔ aw lɔng yu fɔ tek di mɛrɛsin ɛn kam fɔ disayd.
Wetin na di bɛnifit ɛn bad tin dɛn we dis tritmɛnt gɛt?
PARP inhibito dɛn nɔ kin ebul fɔ mɛn kansa ɔltogɛda. Bɔt dɛn kin ɛp di wan dɛn we gɛt sɔm kayn kansa fɔ liv lɔng . Dɛn mɛrɛsin ya kin kɔntrol aw di kansa de gro. dכkta dεn kכl dis fכ inkrεs di "progrεshכn-fri sכvayv rεt." Fɔ tɔk am simpul wan, dɛn kin mek di tɛm we dɛn kin kɔntinyu fɔ kɔntrol di kansa fayn fayn wan ɛn i nɔ kin wɔs. Sɔntɛnde, dɛn kin wok fayn pas kemotɛrapi.
כltu, as tεm de go, sכm kεnsar sεl dεm kin bigin fכ divεlכp "rεsistεns" to dεn dεm ya. Dis min se di drɔgs nɔ de wok igen. Dis kin apin to bitwin 40% ɛn 70% pan di sik pipul dɛm. Sayɛnsman dɛn de tray fɔ ɔndastand wetin mek dis kin apin ɛn dɛn de du risach bɔt nyu we dɛn fɔ mek dɛn mɛrɛsin ya wok fayn.
Lɛ wi no bak bɔt di bad tin dɛn we kin apin to wi.
Lɛk ɛni kansa tritmɛnt, PARP inhibitors kin mek sɔm sayd ɛfɛkt. Bɔt nɔto ɔlman kin gɛt dɛn. Ɛn dɛn kin ebul fɔ kɔntrol bɔku pan dɛn tin ya.
| Kɔmɔn sayd ɛfɛkt dɛn | Di rizin fɔ dat ɔ mɔ tin dɛn |
|---|---|
| Taya ɛn taya | Bɔku tɛm, i kin bi bikɔs ɔf anemia, we na we di rɛd blɔd sɛl dɛn we de na di blɔd de go dɔŋ. |
| Blɔd (e.g., brus, nos blɔd) . | I kin bi bikɔs di blɔd pletlɛt dɛn nɔ bɔku. |
| Infekshɔn dɛn we kin kam bɔku tɛm | If di wayt blɔd sɛl dɛn nɔ bɔku, dat kin mek di bɔdi in imyun sistɛm wik. |
| Nɔs ɛn vɔmit | Dɛn kin tek ɔda mɛrɛsin fɔ kɔntrol dɛn tin ya. |
| Bɛlɛ de pen, blo, ɔ kɔnstipɛshɔn | Dɛn kin kɔntrol am wit chenj dɛn we yu de it ɛn if nid de, yu kin tek mɛrɛsin. |
| Chenj na di teist na di mɔt (dysgeusia) . | Fɔd kin te difrɛn we. |
| We yu de lɔs yu wet, yu de tɔn diziz, yu ed de at | Dis na tin dɛm bak we kin apin to sɔm pipul dɛm. |
Na smɔl tɛm nɔmɔ, sɔm PARP inhibitors kin mek di risk fɔ gɛt wan kayn blɔd kansa we dɛn kɔl acute myeloid leukemia . Bɔt dis na tin we nɔ kin apin so ɔltɛm.
Ustɛm fɔ tɛl yu dɔktɔ wantɛm wantɛm
If yu de tek wan PARP inhibitor, i impɔtant fɔ tɛl yu dɔktɔ if yu gɛt ɛni nyu ɔr we de wɔs sayd ɛfɛkt . I kin chenj di doz ɔ gi am ɔda mɛrɛsin fɔ ɛp wit tin dɛn lɛk nɔys.
Ɛspɛshali if yu gɛt dɛn sik ya:Tɛl yu dɔktɔ ɔ ɔspitul we de trit yu wantɛm wantɛm:
- Sayn dɛm fɔ se yu gɛt infekshɔn: fiva, kol, ɛn shek.
- Nyumonitis simptom dɛm: I nɔ kin izi fɔ blo, yu kin swɛt, yu chɛst kin tayt, ɛn ɔda tin dɛm (Dis na inflammatory condition of the lungs).
- Sayn dɛm fɔ se blɔd dɔn rɔtin: yu leg de swel, yu de fil pen, yu de rɛd ɔ yu chɛst de pen, i nɔ izi fɔ blo.
Mɛsej we dɛn kin kɛr go na os
- PARP Inhibitors na wan kayn "targeted therapy" we de target di DNA ripa sistεm fכ di kεnsar sεl dεm εn destroy dεm.
- dis dεm kin wok bכku fכ kεnsar dεm lεk brεst, ovarian, εn prכstat kεnsar we gεt BRCA jin mכtεshכn.
- Dɛn nɔ kin gi dis tritmɛnt bay injɛkshɔn, bɔt na tablɛt/kapsul we dɛn kin tek ɛvride.
- Pan ɔl we dis nɔ kin mɛn di kansa ɔltogɛda, i kin ɛp di wan dɛn we sik fɔ liv lɔng bay we i kin kɔntrol aw di kansa de gro.
- Lɛk ɔda tritmɛnt dɛn we kin mek pɔsin gɛt kansa, dɛn tin ya kin gɛt bad bad tin dɛn fɔ du. Taya, nɔs, ɛn smɔl blɔd sɛl kin kam.
- I rili impɔtant fɔ mek yu gɛt tayt padi biznɛs wit yu dɔktɔ ɔl di tɛm we yu de trit yu ɛn ripɔt ɛni sayd ɛfɛkt wantɛm wantɛm.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt